Compare Danaher Corporation (DHR) vs Starbucks Corp (SBUX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs Starbucks Corp — how do they compare? Danaher Corporation trades at $219.87 (market cap $152.87B), while Starbucks Corp trades at $90.75 (market cap $106.26B). The key difference: Danaher Corporation is the larger of the two by market cap, and Starbucks Corp pays the higher dividend (2.7%). Which is the better fit depends on your goals — on Pluang, investors hold Danaher Corporation for 69 Days and Starbucks Corp for 190 Days on average.
| DHR | SBUX | |
|---|---|---|
Market Cap | $152.87B | $106.26B |
Volume | 5,228,698 | 30,248,434 |
Sector | Health | Consumer Cyclical |
52-Week High | $242.05 | $108.55 |
52-Week Low | $161.91 | $78.46 |
Typical Hold Time | 69 Days | 190 Days |
Enterprise Value | $175.08B | $125.08B |
Dividend Yield | 0.74% | 2.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $217.46, down 0.47% on the day, with a bullish technical signal from moving averages and support at $214. The company shows strong profitability with a 58.51% gross margin and has beaten EPS estimates for three consecutive quarters. Recent news includes a declared $0.40 dividend payable in October 2026 and significant institutional buying, such as Bank of America's new $993.8 million stake in Q2 2026.
The outlook is positive with a consensus price target of $230.31, implying 5.9% upside, supported by 70% analyst buy ratings. Risks include elevated valuation multiples like a P/E of 38.76 and fluctuating cash flows, but earnings growth in biotechnology and steady revenue provide a solid foundation for investor confidence.
Starbucks (SBUX) trades at $93.21, down 0.4% on the day, amid a bearish technical signal and recent store closure announcements. The stock shows mixed earnings performance with Q1 and Q2 2026 beats but a Q4 2025 miss, while 2025 revenue grew to $37.18B with a net income margin of 5.17%. Analyst consensus is a Buy with a $115.50 price target, but technical indicators suggest near-term pressure with support at $89 and resistance at $96.
The outlook for SBUX hinges on its turnaround strategy execution, including portfolio optimization through store closures. Upside potential exists from analyst targets, but risks include labor relations, competitive pressures, and macroeconomic sensitivity. The stock's high P/E of 53.88 indicates growth expectations must be met for sustained gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About Starbucks Corp
Starbucks Corporation retails, roasts, and provides its own brand of specialty coffee. The Company operates retail locations worldwide and sells whole bean coffees through its sales group, direct response business, supermarkets, and on the world wide web. Starbucks also produces and sells bottled coffee drinks and a line of ice creams.
Read more on SBUX →
